» Articles » PMID: 36900663

Determinants of Acquisition, Persistence, and Clearance of Oncogenic Cervical Human Papillomavirus Infection in the Philippines Using a Multi-Omics Approach: DEFEAT HPV Study Protocol

Abstract

HPV infection is one of the most studied risk factors in cervical cancer-the second most common cancer site and cause of death due to cancer in the Philippines. However, there is a lack of population-based epidemiological data on cervical HPV infection in the Philippines. Local reports on co-infections with other lower genital tract pathogens, commonly reported globally, are also lacking, which emphasizes the need to increase efforts in targeting HPV prevalence, genotype, and distribution. Hence, we aim to determine the molecular epidemiology and natural history of HPV infection among reproductive-age Filipino women using a community-based prospective cohort design. Women from rural and urban centers will be screened until the target sample size of 110 HPV-positive women (55 from rural sites and 55 from urban sites) is reached. Cervical and vaginal swabs will be collected from all screened participants. For HPV-positive patients, HPV genotypes will be determined. One hundred ten healthy controls will be selected from previously screened volunteers. The cases and controls will comprise the multi-omics subset of participants and will be followed up after 6 and 12 months for repeat HPV screening. Metagenomic and metabolomic analyses of the vaginal swabs will also be performed at baseline, after 6 months, and after 12 months. The results of this study will update the prevalence and genotypic distribution of cervical HPV infection among Filipino women, determine whether the current vaccines used for HPV vaccination programs capture the most prevalent high-risk HPV genotypes in the country, and identify vaginal community state types and bacterial taxa associated with the natural history of cervical HPV infection. The results of this study will be used as the basis for developing a biomarker that can help predict the risk of developing persistent cervical HPV infection in Filipino women.

Citing Articles

Human Papillomavirus Carcinogenicity and the Need of New Perspectives: Thoughts from a Retrospective Analysis on Human Papillomavirus Outcomes Conducted at the Hospital University of Bari, Apulia, Italy, between 2011 and 2022.

Del Prete R, Nesta D, Triggiano F, Lorusso M, Garzone S, Vitulano L Diagnostics (Basel). 2024; 14(9).

PMID: 38732382 PMC: 11083870. DOI: 10.3390/diagnostics14090968.


One-pot method for preparing DNA, RNA, and protein for multiomics analysis.

Biedka S, Alkam D, Washam C, Yablonska S, Storey A, Byrum S Commun Biol. 2024; 7(1):324.

PMID: 38485785 PMC: 10940598. DOI: 10.1038/s42003-024-05993-1.

References
1.
Brusselaers N, Shrestha S, van de Wijgert J, Verstraelen H . Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. Am J Obstet Gynecol. 2018; 221(1):9-18.e8. DOI: 10.1016/j.ajog.2018.12.011. View

2.
El-Zein M, Richardson L, Franco E . Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. J Clin Virol. 2015; 76 Suppl 1:S62-S68. PMC: 4789074. DOI: 10.1016/j.jcv.2015.11.020. View

3.
Nugent R, Krohn M, Hillier S . Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991; 29(2):297-301. PMC: 269757. DOI: 10.1128/jcm.29.2.297-301.1991. View

4.
Simelela P . WHO global strategy to eliminate cervical cancer as a public health problem: An opportunity to make it a disease of the past. Int J Gynaecol Obstet. 2020; 152(1):1-3. DOI: 10.1002/ijgo.13484. View

5.
Sha B, Chen H, Wang Q, Zariffard M, Cohen M, Spear G . Utility of Amsel criteria, Nugent score, and quantitative PCR for Gardnerella vaginalis, Mycoplasma hominis, and Lactobacillus spp. for diagnosis of bacterial vaginosis in human immunodeficiency virus-infected women. J Clin Microbiol. 2005; 43(9):4607-12. PMC: 1234056. DOI: 10.1128/JCM.43.9.4607-4612.2005. View